Growth Equity Opportunities 17 LLC 13D and 13G filings for Satsuma Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-05-02 5:26 pm Sale | 2023-04-18 | 13D | Satsuma Pharmaceuticals, Inc. STSA | Growth Equity Opportunities 17 LLC | 0 0.000% | -2,488,587 (Position Closed) | Filing |
| 2023-01-27 4:58 pm Sale | 2023-01-20 | 13D | Satsuma Pharmaceuticals, Inc. STSA | Growth Equity Opportunities 17 LLC | 2,488,587 7.500% | -504,371 (-16.85%) | Filing |
| 2021-03-15 2:52 pm Purchase | 2021-03-03 | 13D | Satsuma Pharmaceuticals, Inc. STSA | Growth Equity Opportunities 17 LLC | 2,992,958 9.500% | 2,992,958 (New Position) | Filing |